Direct Answer
Blood cancer is an umbrella term covering leukaemia, lymphoma and myeloma, together accounting for around 40,000 UK diagnoses each year. UK survival is strong for many types, with childhood ALL cured in over 90% of patients who complete a full funded treatment course. World Aid Network funds cancer treatment for poor patients overseas.
Blood cancer is not a single disease. The term covers three main groups — leukaemia, lymphoma and myeloma — each arising from different blood cell types, behaving differently and requiring different treatments. Together they account for around 40,000 new diagnoses in the UK every year, making blood cancers collectively the third most common cancer type.
What unites leukaemia, lymphoma and myeloma is that they all originate in cells that are produced in the bone marrow or circulate through the lymphatic system. Unlike solid tumours — lung, bowel or breast cancer — blood cancers are systemic diseases that can affect multiple organs simultaneously and require prolonged systemic treatment rather than localised surgery alone.
This guide answers the twenty most commonly searched questions about blood cancer in the UK, drawing on NHS and WHO sources, and examines the profound inequality in blood cancer treatment between the UK and low-income countries where curative therapy is largely inaccessible to poor patients.
What is blood cancer?
Blood cancer is an umbrella term for cancers that originate in blood-forming or lymphoid tissues. The bone marrow — the spongy tissue inside bones — produces all blood cells: red cells that carry oxygen, white cells that fight infection and platelets that form clots. When any of these cell lines undergo malignant transformation, the result is a blood cancer.
The three principal categories are: leukaemia, in which malignant cells originate in the bone marrow and flood the blood; lymphoma, in which malignant lymphocytes accumulate in the lymph nodes and lymphatic organs; and myeloma (or multiple myeloma), in which malignant plasma cells accumulate in the bone marrow and produce abnormal antibody proteins that damage kidneys and bones.
What are the symptoms of blood cancer?
Because blood cancers disrupt normal blood cell production and immune function, symptoms reflect a failure of the systems those cells support. The NHS advises seeing your GP if you notice any of the following persisting for more than two weeks: unexplained fatigue and breathlessness (from anaemia due to low red cell production); frequent, severe or recurrent infections (from failure of normal white cell function); unusual bruising, bleeding gums or prolonged bleeding from cuts (from low platelet count); unexplained weight loss; night sweats that drench clothing; or persistent swelling of lymph nodes in the neck, armpits or groin.
Additional symptoms that are more specific to particular blood cancer types include: bone pain — particularly in the back or ribs — which is a hallmark of myeloma; itching without a rash, which occurs in some lymphomas; and bone or joint pain in children, which can be an early sign of leukaemia. Many blood cancers, particularly the chronic types, produce no symptoms at all in the early stages and are detected incidentally on a routine blood test.
What is leukaemia?
Leukaemia is a cancer of the blood-forming cells in the bone marrow. There are four main types. Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, accounting for around 800 UK cases per year; it progresses rapidly and requires urgent treatment. Acute myeloid leukaemia (AML) affects mainly adults over 60, progresses rapidly and carries the least favourable prognosis of the four types. Chronic myeloid leukaemia (CML) is driven by the BCR-ABL gene fusion (Philadelphia chromosome) and has been transformed by imatinib (Gleevec) into a largely manageable chronic condition. Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia, often diagnosed incidentally in older adults and managed with a watch-and-wait approach for years.
Leukaemia symptoms include: fatigue and breathlessness from anaemia; frequent infections from dysfunctional white cells; easy bruising and bleeding from low platelets; bone or joint pain (particularly in children with ALL); swollen lymph nodes or spleen; night sweats; and unexplained weight loss. In acute leukaemia, these symptoms can develop over days to weeks. In chronic leukaemia, they may be absent for years.
What is lymphoma?
Lymphoma is a cancer of the lymphocytes — white blood cells that circulate through the lymphatic system. It is divided into Hodgkin lymphoma (HL), characterised by Reed-Sternberg cells and accounting for around 2,200 UK cases per year, and non-Hodgkin lymphoma (NHL), a family of over 60 distinct subtypes accounting for around 14,000 UK cases per year. The most common NHL subtypes are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
The hallmark symptom of lymphoma is a painless swelling of one or more lymph nodes — most commonly in the neck, armpits or groin — that persists for more than six weeks. The combination of drenching night sweats, unexplained weight loss of more than 10% of body weight over six months, and fever above 38°C are called 'B symptoms' and are an important staging feature. Other symptoms include itching without a visible rash, breathlessness and unexplained fatigue. In Hodgkin lymphoma, an unusual and classic feature is lymph node pain triggered by drinking alcohol.
What is myeloma?
Multiple myeloma is a cancer of plasma cells — the white blood cells responsible for producing antibodies. Malignant plasma cells accumulate in the bone marrow, crowding out normal blood cell production, weakening bones and producing a dysfunctional antibody protein (paraprotein) that clogs and damages the kidneys. Around 6,500 people are diagnosed with myeloma in the UK every year, almost exclusively in adults over 60.
The CRAB criteria summarise the classic symptoms of myeloma: Calcium elevated in the blood (causing confusion, constipation and thirst); Renal impairment (kidney dysfunction from paraprotein deposits); Anaemia (fatigue and breathlessness from crowded-out red cell production); and Bone lesions (bone pain — typically in the back, ribs or hips — from plasma cell infiltration and osteolytic lesions). Many patients are also susceptible to recurrent infections from impaired normal antibody production. Myeloma is frequently diagnosed after a pathological fracture or incidentally on blood tests showing an elevated protein level.
How is blood cancer diagnosed?
Blood cancer is diagnosed through a combination of blood tests and bone marrow examination. A full blood count (FBC) is typically the first test — it may show abnormal numbers of white cells (high in leukaemia, low in aplastic anaemia), anaemia or low platelets. A blood film examination shows abnormal cell morphology. Serum protein electrophoresis (SPEP) detects the paraprotein of myeloma.
A bone marrow biopsy — in which a small sample of bone marrow is taken from the back of the hip bone under local anaesthetic — is essential for confirming most blood cancer diagnoses, identifying the specific subtype and performing cytogenetic and molecular tests (such as FISH for BCR-ABL in CML, cytogenetics in AML or AL-ALL) that guide treatment decisions. For lymphoma, an excision or core needle biopsy of an enlarged lymph node is the diagnostic gold standard, followed by a PET-CT scan for staging.
What treatment options are available?
Leukaemia treatment depends on the type. AML requires intensive induction chemotherapy (typically daunorubicin and cytarabine) to achieve remission, followed by consolidation chemotherapy or an allogeneic stem cell transplant for high-risk patients. ALL in adults uses prolonged combination chemotherapy protocols over two to three years; newer immunotherapies including blinatumomab and inotuzumab are used for relapsed disease. CML has been transformed by tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) — once-daily oral tablets that achieve deep molecular remission in the majority of patients. CLL is often monitored without treatment for years; when treatment is needed, ibrutinib (a BTK inhibitor), venetoclax and obinutuzumab are the modern standards.
Lymphoma treatment is subtype-dependent. Hodgkin lymphoma is treated with ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) with or without radiotherapy — achieving cure in the majority of patients. The most common aggressive NHL, DLBCL, is treated with R-CHOP chemoimmunotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone). Indolent NHLs such as follicular lymphoma may be observed initially, with rituximab-based treatment used when intervention is required. CAR-T cell therapy is available on the NHS for relapsed/refractory DLBCL. Myeloma is treated with triplet regimens — typically bortezomib, lenalidomide and dexamethasone — followed by autologous stem cell transplant in eligible patients and long-term maintenance therapy.
What is blood cancer survival rates UK?
Survival rates vary substantially across blood cancer types. For leukaemia: childhood ALL has a five-year survival rate of over 90% with modern treatment — one of the most dramatic improvements in oncology over the past 50 years. Adult AML has a five-year survival of approximately 25–30%, making it the most challenging leukaemia subtype. CML five-year survival now exceeds 90% due to tyrosine kinase inhibitors. CLL five-year survival exceeds 85%. For lymphoma: Hodgkin lymphoma five-year survival exceeds 85%, making it one of the most curable cancers. DLBCL five-year survival is approximately 60–65% with R-CHOP. Follicular lymphoma has a median survival exceeding 15 years, though it is rarely curable. For myeloma: five-year survival has improved to approximately 50–55% with modern triplet therapy and transplant, though the disease remains incurable in the majority of patients.
These figures reflect UK outcomes where treatment is fully funded by the NHS. In low-income countries, where patients pay for treatment out of pocket, outcomes are dramatically worse — not because the biology is different, but because chemotherapy courses are abandoned mid-way due to cost.
Why stopping blood cancer treatment mid-course is so dangerous?
A critical aspect of blood cancer treatment that distinguishes it from many solid tumour cancers is that stopping treatment mid-course due to cost is clinically more dangerous than not starting at all. Blood cancer chemotherapy regimens are cumulative protocols — each cycle builds on the last, driving residual cancer cells to undetectable levels. Stopping early allows the remaining malignant cells — which have already been exposed to the drugs — to develop resistance mechanisms and regrow as a drug-resistant relapse.
In practice, this means a patient with acute leukaemia who starts a chemotherapy protocol but cannot fund the full course will relapse with a disease that responds poorly to further treatment. The prognosis of relapsed drug-resistant leukaemia is significantly worse than that of untreated leukaemia. This is why continuity of funding — ensuring a patient can complete the full treatment course — is not optional but life-critical. World Aid Network's Cancer Emergency Appeal specifically prioritises mid-course continuity funding for blood cancer patients whose treatment is at risk of abandonment.
What are blood cancer in low-income countries?
In Pakistan, Indonesia and Malaysia, blood cancers represent a significant and growing burden. Acute lymphoblastic leukaemia is the most common childhood cancer in all three countries. Lymphoma — particularly non-Hodgkin lymphoma — is among the top ten most common cancers by incidence. Myeloma, while less common, disproportionately affects older patients who may have no access to the costly drugs required for treatment.
The fundamental barrier is cost. Chemotherapy drugs, bone marrow biopsy procedures, haematology specialist consultations and the years-long treatment courses required for blood cancers represent an impossible financial burden for low-income families. In the UK, all of this is funded by the NHS. In Pakistan, Indonesia and Malaysia, most patients pay out of pocket. A full course of ALL treatment that costs tens of thousands of pounds in the UK must be funded by a family whose annual income may be a few hundred pounds. Without donor support, these patients simply cannot be treated.
Key takeaways
- Blood cancer is an umbrella term covering three main types: leukaemia (bone marrow and blood), lymphoma (lymphatic system) and myeloma (plasma cells). Together they account for around 40,000 UK diagnoses per year.
- Key symptoms shared across blood cancers include unexplained fatigue, frequent infections, unusual bruising or bleeding, night sweats and unexplained weight loss. Myeloma also causes bone pain; lymphoma causes painless swollen lymph nodes.
- Stopping blood cancer chemotherapy mid-course due to cost is more dangerous than delayed treatment — residual cells develop drug resistance, leading to relapse with a worse prognosis. Treatment continuity funding is life-critical.
- UK survival rates are strong for many blood cancers (ALL in children >90%, Hodgkin lymphoma >85%, CML >90%) but depend entirely on completing the full funded treatment course. In low-income countries, outcomes are dramatically lower because treatment is unaffordable.
- World Aid Network funds blood cancer treatment — leukaemia, lymphoma and myeloma — for poor patients in Pakistan, Indonesia and Malaysia through locally-licensed haematologists and oncologists. Continuity of care is our priority.
Your donation funds treatment — not research
In the UK, cancer survival rates are among the world's best. In Pakistan, Indonesia and Malaysia, the same cancers kill at far higher rates — because treatment is out of reach for poor patients. World Aid Network funds cancer treatment through locally-licensed oncologists, directly closing that gap.
→ Cancer treatment programmesFrequently asked questions
What is the difference between leukaemia, lymphoma and myeloma?
Leukaemia originates in blood-forming cells in the bone marrow, causing abnormal white blood cells to flood the blood. Lymphoma originates in lymphocytes and accumulates in lymph nodes and lymphoid organs. Myeloma originates in plasma cells in the bone marrow, producing a dysfunctional antibody protein that damages kidneys and bones. All three are 'blood cancers' because they arise from blood or lymphoid cells, but they are distinct diseases with different treatments and outcomes.
What are the early warning signs of blood cancer?
The NHS advises seeing your GP if you notice: unexplained and persistent fatigue or breathlessness; frequent or severe infections; unusual bruising or bleeding; unexplained weight loss; night sweats that soak your clothing; or swollen lymph nodes in the neck, armpit or groin that persist for more than six weeks. In myeloma, persistent back or bone pain is an additional warning sign. Many blood cancers have no symptoms in early stages and are detected on routine blood tests — which is why a full blood count is important.
Is blood cancer curable?
It depends on the type. Childhood ALL is curable in over 90% of patients who complete a full funded treatment course — one of modern oncology's greatest achievements. Hodgkin lymphoma is curable in the majority of patients with chemotherapy. CML is controlled, though not always cured, with daily targeted therapy tablets. AML has around a 25–30% five-year survival. Myeloma is rarely cured but highly treatable, with modern therapy producing remissions lasting many years. The prognosis is always best when treatment is started promptly and completed fully.
How is blood cancer treated on the NHS?
All blood cancers are treated free at the point of use on the NHS. Treatment includes chemotherapy, targeted therapy (such as imatinib for CML, ibrutinib for CLL), immunotherapy (rituximab for lymphoma), bone marrow or stem cell transplant, radiotherapy and supportive care including blood transfusions and growth factors. NICE approves newer treatments including CAR-T cell therapy for relapsed/refractory DLBCL and other B-cell lymphomas. Haematology multidisciplinary teams at specialist centres manage all diagnoses.
Why does World Aid Network fund blood cancer treatment?
Blood cancer treatment — leukaemia, lymphoma and myeloma — is included within our charitable Objects, which cover cancer treatment of all types for poor patients in Pakistan, Indonesia and Malaysia. In these countries, patients pay out of pocket for haematology consultations, chemotherapy drugs and bone marrow procedures. A full leukaemia treatment course that takes two or more years and costs tens of thousands of pounds is financially catastrophic for a low-income family. We fund the treatment costs that ensure patients receive — and complete — the care their doctor has recommended.
Can I donate in memory of someone who died of a blood cancer?
Yes. The Cancer Emergency Appeal accepts memorial donations for leukaemia, lymphoma, myeloma and all other blood cancers. Please contact [email protected] and we will set up a dedicated tribute page in their memory.
This article was reviewed by the World Aid Network editorial team for factual accuracy against WHO, NHS, HMRC and Charity Commission sources. World Aid Network is a UK Charitable Incorporated Organisation (charity registration in progress), governed by named trustees.